Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma

Haematologica

Volumn 89, Issue 5, 2004, Pages 567-577

  Abildgaard, Niels ^a   Brixen, Kim ^a,b   Eriksen, Erik Fink ^a   Kristensen, Jens Erik ^a   Nielsen, Johan Lanng ^a   Heickendorff, Lene ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Biochemical markers of bone metabolism; Carboxy terminal telopeptide of collagen type I (ICTP); Multiple myeloma; Osteolytic bone disease

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; AMINOTRANSFERASE; ANTHRACYCLINE; BETA 2 MICROGLOBULIN; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; CREATININE; GLUCOCORTICOID; HEMOGLOBIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MELPHALAN; OSTEOCALCIN; PREDNISONE; PROCOLLAGEN; VINCRISTINE;

ADULT; AGED; ARTICLE; BONE; BONE ATROPHY; BONE DENSITY; BONE INJURY; BONE MINERAL; BONE RADIOGRAPHY; CLINICAL ARTICLE; DENSITOMETRY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HYDRATION; MALE; MULTIPLE MYELOMA; OSSIFICATION; PATHOLOGIC FRACTURE; RADIOIMMUNOASSAY; SEQUENTIAL ANALYSIS; SKELETON RADIOGRAPHY; SPECTROPHOTOMETRY; VERTEBRA FRACTURE;

ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY; BONE RESORPTION; COLLAGEN; COLLAGEN TYPE I; DENSITOMETRY, X-RAY; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PEPTIDE FRAGMENTS; PEPTIDES; PROCOLLAGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 2542500652     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Bataille R, Chappard D, Marcelli C, Dessauw P, Sany J, Baldet P, et al. Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. J Clin Oncol 1989;7:1909-14.
2. Bataille R, Chappard D, Marcelli C, Rossi JF, Dessauw P, Baldet P, et al. Osteoblast stimulation in multiple myeloma lacking lytic bone lesions. Br J Haematol 1990;76:484-7.
3. Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N, et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 2001;98:11581-6.
4. Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 2002;116:278-90.
5. Abildgaard N, Glerup H, Rungby J, Bendix-Hansen K, Kassem M, Brixen K, et al. Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma. Eur J Haematol 2000;64:121-9.
6. Corso A, Arcaini L, Mangiacavalli S, Astori C, Orlandi E, Lorenzi A, et al. Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients. Haematologica 2001;86:394-8.
7. Abildgaard N, Bentzen SM, Nielsen JL, Heickendorff L. Serum markers of bone metabolism in multiple myeloma: prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP). Nordic Myeloma Study Group (NMSG). Br J Haematol 1997;96:103-10.
8. Carlson K, Larsson A, Simonsson B, Turesson I, Westin J, Ljunghall S. Evaluation of bone disease in multiple myeloma: a comparison between the resorption markers urinary deoxypyridinoline/creatinine (DPD) and serum ICTP, and an evaluation of the DPD/osteocalcin and ICTP/osteocalcin ratios. Eur J Haematol 1999;62:300-6.
9. Fonseca R, Trendle MC, Leong T, Kyle RA, Oken MM, Kay NE, et al. Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients. Br J Haematol 2000;109:24-9.
10. Elomaa I, Virkkunen P, Risteli L, Risteli J. Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer 1992;66:337-41.
11. Withold W, Arning M, Schwarz M, Wolf HH, Schneider W. Monitoring of multiple myeloma patients by simultaneously measuring marker substances of bone resorption and formation. Clin Chim Acta 1998;269:21-30.
12. Peest D, Deicher H, Fett W, Harms P, Braun HJ, Planker M, et al. Pyridinium cross-links in multiple myeloma: correlation with clinical parameters and use for monitoring of intravenous clodronate therapy: a pilot study of the German Myeloma Treatment Group (GMTG). Eur J Cancer 1996;32A:2053-7.
13. Pecherstorfer M, Seibel MJ, Woitge HW, Horn E, Schuster J, Neuda J, et al. Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: quantification by urinary pyridinium cross-links of collagen. Blood 1997;90:3743-50.
14. Carlson K, Simonsson B, Ljunghall S. Acute effects of high-dose chemotherapy followed by bone marrow transplantation on serum markers of bone metabolism. Calcif Tissue Int 1994;55:408-11.
15. Elomaa I, Risteli L, Laakso M, Lahtinen R, Virkkunen P, Risteli J. Monitoring the action of clodronate with type I collagen metabolites in multiple myeloma. Eur J Cancer 1996;32:1166-70.
16. Terpos E, Palermos J, Tsionos K, Anargyrou K, Viniou N, Papassavas P, et al. Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma. Eur J Haematol 2000;65:331-6.
17. Clark RE, Flory AJ, Ion EM, Woodcock BE, Durham BH, Fraser WD. Biochemical markers of bone turnover following high-dose chemotherapy and autografting in multiple myeloma. Blood 2000;96:2697-702.
18. Abildgaard N, Brixen K, Kristensen JE, Eriksen EF, Nielsen JL, Heickendorff L. Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy. Br J Haematol 2003;120:235-42.
19. Abildgaard N, Brixen K, Kristensen JE, Vejlgaard T, Charles P, Nielsen JL. Assessment of bone involvement in patients with multiple myeloma using bone densitometry. Eur J Haematol 1996;57:370-6.
20. Mariette X, Khalifa P, Ravaud P, Frija J, Laval-Jeantet M, Chastang C, et al. Bone densitometry in patients with multiple myeloma. Am J Med 1992;93:595-8.
21. Mariette X, Bergot C, Ravaud P, Roux C, Laval-Jeantet M, Brouet JC, et al. Evolution of bone densitometry in patients with myeloma treated with conventional or intensive therapy. Cancer 1995;76:1559-63.
22. Roux C, Ravaud P, Cohen-Solal M, de Vernejoul MC, Guillemant S, Cherruau B, et al. Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma. Bone 1994;15:41-9.
23. Diamond T, Levy S, Day P, Barbagallo S, Manoharan A, Kwan YK. Biochemical, histomorphometric and densitometric changes in patients with multiple myeloma: effects of glucocorticoid therapy and disease activity. Br J Haematol 1997;97:641-8.
24. Dhodapkar MV, Weinstein R, Tricot G, Jagannath S, Parfitt AM, Manolagas SC, et al. Biologic and therapeutic determinants of bone mineral density in multiple myeloma. Leuk Lymphoma 1998;32:121-7.
25. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-54.
26. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 1993;39:635-40.
27. Sassi ML, Eriksen H, Risteli L, Niemi S, Mansell J, Gowen M, et al. Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K. Bone 2000;26:367-73.
28. Garnero P, Ferreras M, Karsdal MA, Nicamhlaoibh R, Risteli J, Borel O, et al. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 2003;18:859-67.
29. Hanson DA, Weis MA, Bollen AM, Maslan SL, Singer FR, Eyre DR. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 1992;7:1251-8.
30. Melkko J, Kauppila S, Niemi S, Risteli L, Haukipuro K, Jukkola A, et al. Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin Chem 1996;42:947-54.
31. Melkko J, Niemi S, Risteli L, Risteli J. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 1990;36:1328-32.
32. Price PA, Nishimoto SK. Radioimmunoassay for the vitamin K-dependent protein of bone and its discovery in plasma. Proc Natl Acad Sci USA 1980;77:2234-8.
33. Behr W, Barnert J. Quantification of bone alkaline phosphatase in serum by precipitation with wheat-germ lectin: a simplified method and its clinical plausibility. Clin Chem 1986;32:1960-6.
34. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-23.
35. Bataille R, Chappard D, Basle M. Excessive bone resorption in human plasmacytomas: direct induction by tumour cells in vivo. Br J Haematol 1995;90:721-4.
36. Taube T, Beneton MN, McCloskey EV, Rogers S, Greaves M, Kanis JA. Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol 1992;49:192-8.
37. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998;91:3-21.